Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab

As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammat...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvati, Lorenzo, Occhipinti, Mariaelena, Gori, Leonardo, Ciani, Luca, Mazzoni, Alessio, Maggi, Laura, Capone, Manuela, Parronchi, Paola, Liotta, Francesco, Miele, Vittorio, Annunziato, Francesco, Lavorini, Federico, Cosmi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Immunological Societies. Published by Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644186/
https://www.ncbi.nlm.nih.gov/pubmed/33161002
http://dx.doi.org/10.1016/j.imlet.2020.10.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644186/
https://www.ncbi.nlm.nih.gov/pubmed/33161002
http://dx.doi.org/10.1016/j.imlet.2020.10.009

Ejemplares similares